The prevalence of asymptomatic Cryptococcal antigenemia in people living with human immunodeficiency virus with severe immunosuppression
DOI:
https://doi.org/10.18203/2349-3933.ijam20252531Keywords:
Cryptococcal meningitis, High mortality, Low CD4 count, Cryptococcal antigen, Asymptomatic patients, Routine screeningAbstract
Background: Cryptococcal meningitis is a life-threatening disease among human immunodeficiency virus (HIV) patients specially with severe immunosuppression. Cryptococcal antigen (CrAg) can be detected well before the development of disease as CrAg circulates before the progressing to meningitis so if serum CrAg positive in asymptomatic patients the patients may develop cryptococcal meningitis in future so treatment in asymptomatic patients who are positive for CrAg can reduce the mortality.
Methods: This was cross-sectional study in which CrAg was tested among 84 PLHIV patient with CD4 count of less than 200/mm3 using latex agglutination test. Age, gender, World Health Organization (WHO) staging, ART regimen, haemoglobin level and presence of other opportunistic infection were added as determinants of CrAg positivity.
Results: Mean age among the study subjects was 39.19 years. 72.6% were males and 27.4% were females. 77.4% belong stage 1 of WHO,6% to stage 2,15.4% to stage 3, and 1.2% to stage 4. Mean CD4 count of subjects was 94.70 cells/mm3. 54.7% of the subjects had CD4 count of less than 100cells/mm3 and 45.3% subjects had CD4 count of more than 100 cells/mm3 subjects were tested positive for CrAg with prevalence being 6%. Mean CD4 count in subjects who tested positive was 34.20 cells/mm3 and in subjects who tested negative was 98.53 cells/mm3.
Conclusions: Prevalence of asymptomatic cryptococcal antigenemia was found to be 6% in PLHIV with CD4 count less than 200 cells/mm3 and prevalence was about 10.8% in subjects with CD4 count of less than 100 cells/mm3 compared to 0% in subjects with CD4 count of 100-200 cells/mm3. As the mortality of cryptococcal meningitis is very high and testing CrAg is cost effective if done in large scale.
Metrics
References
Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS. 2009;23:525-30.
Baradkar V, Mathur M, De A, Kumar S, Rathi M. Prevalence and clinical presentation of Cryptococcal meningitis among HIV seropositive patients. Indian J Sex Transm Dis. 2009;30:19-22. DOI: https://doi.org/10.4103/0253-7184.55474
Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS. 2009;23(4):525-30. DOI: https://doi.org/10.1097/QAD.0b013e328322ffac
French N, Gray K, Watera C, Nakiyingi J, Lugada E, Moore M, et al. Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. AIDS. 2002;16(7):1031-8. DOI: https://doi.org/10.1097/00002030-200205030-00009
Kato M, Long NH, Duong BD, Nhan do T, Nguyen TT, Hai NH, et al. Enhancing the benefits of antiretroviral therapy in Vietnam: towards ending AIDS. Curr HIV/AIDS Rep. 2014;11:487-95. DOI: https://doi.org/10.1007/s11904-014-0235-7
Rajasingham R, Meya DB, Boulware DR. Integrating Cryptococcal Antigen Screening and Pre-emptive Treatment into Routine HIV care. J Acquir Immune Defic Syndr. 2012;59:85-9. DOI: https://doi.org/10.1097/QAI.0b013e31824c837e
Meya DB, Manabe YC, Castelnuovo B, Cook BA, Elbireer AM, Kambugu A, et al. Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < 100cells/ml to start HIV therapy in resource limited setting. Clin Infect Dis. 2010;51:448-55.
Jackson AT, van der Horst CM. Editorial Commentary: Cryptococcosis in AIDS: New Data but Questions Remain. Clin Infect Dis. 2016;62:588-9. DOI: https://doi.org/10.1093/cid/civ939
McKenney J, Smith RM, Chiller TM, Detels R, French A, Margolick J, et al; Centers for Disease Control and Prevention.: Prevalence and correlates of cryptococcal antigen positivity among AIDS patients--United States, 1986-2012. MMWR Morb Mortal Wkly Rep. 2014;63:585-7. DOI: https://doi.org/10.1093/cid/ciu937
Anuradha S, Narayana AH, Dewan R, Kaur R, Rajeshwari K. Asymptomatic Cryptococcal Antigenemia in People Living with HIV (PLHIV) with Severe Immunosuppression: Is Routine CrAg Screening Indicated in India? J Assoc Physicians India. 2017;65(4):14-17.
Kumar S, Wanchu A, Chakrabarti A, Sharma A, Bambery P, Singh S. Cryptococcal meningitis in HIV infected: experience from a North Indian tertiary center. Neurol India. 2008;56(4):444-9. DOI: https://doi.org/10.4103/0028-3886.44823
Meya DB, Manabe YC, Castelnuovo B, Cook BA, Elbireer AM, Kambugu A, et al. Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings. Clin Infect Dis. 2010;51(4):448-55. DOI: https://doi.org/10.1086/655143
Ford N, Shubber Z, Jarvis JN, Chiller T, Greene G, Migone C, et al. CD4 Cell Count Threshold for Cryptococcal Antigen Screening of HIV-Infected Individuals: A Systematic Review and Meta-analysis. Clin Infect Dis. 2018;66(suppl_2):S152-9. DOI: https://doi.org/10.1093/cid/cix1143
World Health Organization. Rapid Advice: Diagnosis, prevention and management of Cryptococcal disease in HIV -infected adults, adolescents and children. 2011. Available at: whqlibdoc.who.int/ publications/2011/97892415029 79_eng. pdf. Accessed on 12 May 2025.
Downloads
Published
How to Cite
Issue
Section
